For: | Johansson H, Andersson R, Bauden M, Hammes S, Holdenrieder S, Ansari D. Immune checkpoint therapy for pancreatic cancer. World J Gastroenterol 2016; 22(43): 9457-9476 [PMID: 27920468 DOI: 10.3748/wjg.v22.i43.9457] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v22/i43/9457.htm |
Number | Citing Articles |
1 |
Javed Mahmood, Allen A. Alexander, Santanu Samanta, Shriya Kamlapurkar, Prerna Singh, Ali Saeed, France Carrier, Xuefang Cao, Hem D Shukla, Zeljko Vujaskovic. A Combination of Radiotherapy, Hyperthermia, and Immunotherapy Inhibits Pancreatic Tumor Growth and Prolongs the Survival of Mice. Cancers 2020; 12(4): 1015 doi: 10.3390/cancers12041015
|
2 |
Craig Grobbelaar, Mpho Kgomo, Peace Mabeta. Angiogenesis and Pancreatic Cancer: Novel Approaches to Overcome
Treatment Resistance. Current Cancer Drug Targets 2024; 24(11): 1116 doi: 10.2174/0115680096284588240105051402
|
3 |
Bhalchandra Mirlekar, Daniel Michaud, Samuel J. Lee, Nancy P. Kren, Cameron Harris, Kevin Greene, Emily C. Goldman, Gaorav P. Gupta, Ryan C. Fields, William G. Hawkins, David G. DeNardo, Naim U. Rashid, Jen Jen Yeh, Autumn J. McRee, Benjamin G. Vincent, Dario A.A. Vignali, Yuliya Pylayeva-Gupta. B cell–Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer. Cancer Immunology Research 2020; 8(3): 292 doi: 10.1158/2326-6066.CIR-19-0349
|
4 |
Ibrahim Eissa, Itzel Bustos-Villalobos, Toru Ichinose, Shigeru Matsumura, Yoshinori Naoe, Noriyuki Miyajima, Daishi Morimoto, Nobuaki Mukoyama, Wu Zhiwen, Maki Tanaka, Hitoki Hasegawa, Seiji Sumigama, Branko Aleksic, Yasuhiro Kodera, Hideki Kasuya. The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers. Cancers 2018; 10(10): 356 doi: 10.3390/cancers10100356
|
5 |
Darya Javadrashid, Amir Baghbanzadeh, Nima Hemmat, Khalil Hajiasgharzadeh, Niloufar Sadat Nourbakhsh, Ziba Lotfi, Behzad Baradaran. Envisioning the immune system to determine its role in pancreatic ductal adenocarcinoma: Culprit or victim?. Immunology Letters 2021; 232: 48 doi: 10.1016/j.imlet.2021.02.009
|
6 |
Lin Li, Tai Ren, Ke Liu, Mao-Lan Li, Ya-Jun Geng, Yang Yang, Huai-Feng Li, Xue-Chuan Li, Run-Fa Bao, Yi-Jun Shu, Hao Weng, Wei Gong, Wan Yee Lau, Xiang-Song Wu, Ying-Bin Liu. Development and Validation of a Prognostic Nomogram Based on the Systemic Immune-Inflammation Index for Resectable Gallbladder Cancer to Predict Survival and Chemotherapy Benefit. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.692647
|
7 |
Mei Gao, Miranda Lin, Richard A. Moffitt, Marcela A. Salazar, Jinha Park, Jeffrey Vacirca, Chuan Huang, Kenneth R. Shroyer, Minsig Choi, Georgios V. Georgakis, Aaron R. Sasson, Mark A. Talamini, Joseph Kim. Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer. British Journal of Cancer 2019; 120(1): 88 doi: 10.1038/s41416-018-0298-0
|
8 |
Harshul Pandit, Young K. Hong, Yan Li, Jack Rostas, Zachary Pulliam, Su Ping Li, Robert C. G. Martin. Evaluating the Regulatory Immunomodulation Effect of Irreversible Electroporation (IRE) in Pancreatic Adenocarcinoma. Annals of Surgical Oncology 2019; 26(3): 800 doi: 10.1245/s10434-018-07144-3
|
9 |
Sumiyuki Nishida, Takeshi Ishikawa, Shinichi Egawa, Shigeo Koido, Hiroaki Yanagimoto, Jun Ishii, Yoshihide Kanno, Satoshi Kokura, Hiroaki Yasuda, Mari Saito Oba, Maho Sato, Soyoko Morimoto, Fumihiro Fujiki, Hidetoshi Eguchi, Hiroaki Nagano, Atsushi Kumanogoh, Michiaki Unno, Masanori Kon, Hideaki Shimada, Kei Ito, Sadamu Homma, Yoshihiro Oka, Satoshi Morita, Haruo Sugiyama. Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study. Cancer Immunology Research 2018; 6(3): 320 doi: 10.1158/2326-6066.CIR-17-0386
|
10 |
Hsuan‐Chen Liu, Daniel Davila Gonzalez, Dixita Ishani Viswanath, Robin Shae Vander Pol, Shani Zakiya Saunders, Nicola Di Trani, Yitian Xu, Junjun Zheng, Shu‐Hsia Chen, Corrine Ying Xuan Chua, Alessandro Grattoni. Sustained Intratumoral Administration of Agonist CD40 Antibody Overcomes Immunosuppressive Tumor Microenvironment in Pancreatic Cancer. Advanced Science 2023; 10(9) doi: 10.1002/advs.202206873
|
11 |
Divya Murthy, Kuldeep S. Attri, Pankaj K. Singh. Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics. Frontiers in Physiology 2018; 9 doi: 10.3389/fphys.2018.00335
|
12 |
Kaiwen Wu, Ye Liu, Lei Liu, Yunlan Peng, Honglin Pang, Xiaobin Sun, Demeng Xia. Emerging Trends and Research Foci in Tumor Microenvironment of Pancreatic Cancer: A Bibliometric and Visualized Study. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.810774
|
13 |
Trond A Buanes. Role of surgery in pancreatic cancer. World Journal of Gastroenterology 2017; 23(21): 3765-3770 doi: 10.3748/wjg.v23.i21.3765
|
14 |
Molecular Processes Involved in Pancreatic Cancer and Therapeutics. Current Chemical Biology 2021; 15(1): 85 doi: 10.2174/2212796814999201008130819
|
15 |
Maria Zagorulya, Ellen Duong, Stefani Spranger. Impact of anatomic site on antigen-presenting cells in cancer. Journal for ImmunoTherapy of Cancer 2020; 8(2): e001204 doi: 10.1136/jitc-2020-001204
|
16 |
Thomas Seufferlein, Julia Mayerle, Stefan Böck, Thomas Brunner, Thomas J. Ettrich, Lars Grenacher, Thomas Mathias Gress, Thilo Hackert, Volker Heinemann, Angelika Kestler, Marianne Sinn, Andrea Tannapfel, Ulrich Wedding, Waldemar Uhl. S3-Leitlinie zum exokrinen Pankreaskarzinom – Langversion 2.0 – Dezember 2021 – AWMF-Registernummer: 032/010OL. Zeitschrift für Gastroenterologie 2022; 60(11): e812 doi: 10.1055/a-1856-7346
|
17 |
Chin-King Looi, Felicia Fei-Lei Chung, Chee-Onn Leong, Shew-Fung Wong, Rozita Rosli, Chun-Wai Mai. Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment. Journal of Experimental & Clinical Cancer Research 2019; 38(1) doi: 10.1186/s13046-019-1153-8
|
18 |
Didem Saka, Muazzez Gökalp, Betül Piyade, Nedim Can Cevik, Elif Arik Sever, Derya Unutmaz, Güralp O. Ceyhan, Ihsan Ekin Demir, Hande Asimgil. Mechanisms of T-Cell Exhaustion in Pancreatic Cancer. Cancers 2020; 12(8): 2274 doi: 10.3390/cancers12082274
|
19 |
Jiangang Zhao, Jiahui Li, Hans A. Schlößer, Felix Popp, Marie Christine Popp, Hakan Alakus, Karl-Walter Jauch, Christiane J. Bruns, Yue Zhao. Targeting Cancer Stem Cells and Their Niche: Current Therapeutic Implications and Challenges in Pancreatic Cancer. Stem Cells International 2017; 2017: 1 doi: 10.1155/2017/6012810
|
20 |
Yang Huang, Xu Yan, Tian Ren, Fan Yi, Qi Li, Chunyang Zhang. The safety and efficacy of chemotherapy combined with immunotherapy for pancreatic cancer. Medicine 2021; 100(29): e26673 doi: 10.1097/MD.0000000000026673
|
21 |
Bryan Sisk, Eric Kodish. Ethical Issues in Pediatric Hematology/Oncology. 2020; : 111 doi: 10.1007/978-3-030-22684-8_7
|
22 |
Margareta Heby, Sebastian Lundgren, Björn Nodin, Jacob Elebro, Jakob Eberhard, Karin Jirström. Relationship between mismatch repair immunophenotype and long-term survival in patients with resected periampullary adenocarcinoma. Journal of Translational Medicine 2018; 16(1) doi: 10.1186/s12967-018-1444-4
|
23 |
Zhen J. Wang, Hina Arif-Tiwari, Atif Zaheer, Sanaz Ameli, Priya R. Bhosale, Richard K. Do, Ajit H. Goenka, Alexander R. Guimares, Guillermo P. Sangster, Erik V. Soloff, Eric P. Tamm, Marc Zins, Avinash R. Kambadakone. Therapeutic response assessment in pancreatic ductal adenocarcinoma: society of abdominal radiology review paper on the role of morphological and functional imaging techniques. Abdominal Radiology 2020; 45(12): 4273 doi: 10.1007/s00261-020-02723-z
|
24 |
Dennis Kobelt, Jessica Pahle, Wolfgang Walther. Gene Therapy of Cancer. Methods in Molecular Biology 2022; 2521: 1 doi: 10.1007/978-1-0716-2441-8_1
|
25 |
Thomas Seufferlein, Julia Mayerle, Stefan Boeck, Thomas Brunner, Thomas J. Ettrich, Lars Grenacher, Thomas Mathias Gress, Thilo Hackert, Volker Heinemann, Angelika Kestler, Marianne Sinn, Andrea Tannapfel, Ulrich Wedding, Waldemar Uhl. S3-Leitlinie Exokrines Pankreaskarzinom – Version 3.1. Zeitschrift für Gastroenterologie 2024; 62(10): e874 doi: 10.1055/a-2338-3533
|
26 |
Gaetan Aime Noubissi Nzeteu, Bernhard F. Gibbs, Nika Kotnik, Achim Troja, Maximilian Bockhorn, N. Helge Meyer. Nanoparticle-based immunotherapy of pancreatic cancer. Frontiers in Molecular Biosciences 2022; 9 doi: 10.3389/fmolb.2022.948898
|
27 |
Nicola Gaianigo, Davide Melisi, Carmine Carbone. EMT and Treatment Resistance in Pancreatic Cancer. Cancers 2017; 9(9): 122 doi: 10.3390/cancers9090122
|
28 |
Sultan Abdullah Alomari, Ahmed Sami Alfaqihi, Khalid Abdullah Alzahrani, Khalid Hassan Alzahrani, Khalid Mohammed Alzahrani, Khalid Abdulrahman Alzahrani, Abdulrahman Ahmed Asiri, Amjad Ali Durayb, Abdulaziz Marzouq Aloatibi, Mohammed Bassam Ghandourah. An Overview on the Role of Surgery in Resectable Pancreatic Tumors, Literature Review. Pharmacophore 2021; 12(4): 86 doi: 10.51847/RxWepx87LV
|
29 |
Daniel R. Principe, Alex Park, Matthew J. Dorman, Sandeep Kumar, Navin Viswakarma, Jonathan Rubin, Carolina Torres, Ronald McKinney, Hidayatullah G. Munshi, Paul J. Grippo, Ajay Rana. TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell–Mediated Regression of Pancreatic Cancer. Molecular Cancer Therapeutics 2019; 18(3): 613 doi: 10.1158/1535-7163.MCT-18-0850
|
30 |
Seyed Hossein Kiaie, Mohammad Javad Sanaei, Masoud Heshmati, Zahra Asadzadeh, Iman Azimi, Saleh Hadidi, Reza Jafari, Behzad Baradaran. Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development. Acta Pharmaceutica Sinica B 2021; 11(5): 1083 doi: 10.1016/j.apsb.2020.12.011
|
31 |
Roland Andersson, Carlos-Filipe Pereira, Monika Bauden, Daniel Ansari. Is Immunotherapy the Holy Grail for Pancreatic Cancer?. Immunotherapy 2019; 11(17): 1435 doi: 10.2217/imt-2019-0164
|
32 |
Matthew R Woeste, Rejeena Shrestha, Anne E Geller, Shu Li, Diego Montoya-Durango, Chuanlin Ding, Xiaoling Hu, Hong Li, Aaron Puckett, Robert A Mitchell, Traci Hayat, Min Tan, Yan Li, Kelly M McMasters, Robert C G Martin, Jun Yan. Irreversible electroporation augments β-glucan induced trained innate immunity for the treatment of pancreatic ductal adenocarcinoma. Journal for ImmunoTherapy of Cancer 2023; 11(4): e006221 doi: 10.1136/jitc-2022-006221
|
33 |
Ildikó Fritz, Philippe Wagner, Håkan Olsson. Improved survival in several cancers with use of H1-antihistamines desloratadine and loratadine. Translational Oncology 2021; 14(4): 101029 doi: 10.1016/j.tranon.2021.101029
|
34 |
Suresh Chava, Meher B. Gayatri, Aramati B.M. Reddy. Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy. 2019; : 25 doi: 10.1016/B978-0-12-817661-0.00003-2
|
35 |
Stephan Kruger, Marie-Louise Legenstein, Verena Rösgen, Michael Haas, Dominik Paul Modest, Christoph Benedikt Westphalen, Steffen Ormanns, Thomas Kirchner, Volker Heinemann, Stefan Holdenrieder, Stefan Boeck. Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. OncoImmunology 2017; 6(5): e1310358 doi: 10.1080/2162402X.2017.1310358
|
36 |
Sina Abdkarimi, Saiedeh Razi Soofiyani, Goli Elham, Hossein Mashhadi Abdolahi, Elham Safarzadeh, Behzad Baradaran. Targeting immune checkpoints: Building better therapeutic puzzle in pancreatic cancer combination therapy. European Journal of Cancer Care 2020; 29(5) doi: 10.1111/ecc.13268
|
37 |
Ning Pu, Wenhui Lou, Jun Yu. PD-1 immunotherapy in pancreatic cancer: current status. Journal of Pancreatology 2019; 2(1): 6 doi: 10.1097/JP9.0000000000000010
|
38 |
Wenxin Qi, Qian Liu, Wenjun Fu, Jiaming Shi, Minmin Shi, Songqi Duan, Zhe Li, Shaohua Song, Jiao Wang, Yihao Liu. BHLHE40, a potential immune therapy target, regulated by FGD5-AS1/miR-15a-5p in pancreatic cancer. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-43577-x
|
39 |
Adrian M. J. Pokorny, Venessa T. Chin, Adnan M. Nagrial, Desmond Yip, Lorraine A. Chantrill. Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future. Internal Medicine Journal 2018; 48(6): 637 doi: 10.1111/imj.13810
|
40 |
Glen J. Weiss, Lisa Blaydorn, Julia Beck, Kirsten Bornemann-Kolatzki, Howard Urnovitz, Ekkhard Schütz, Vivek Khemka. Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. Investigational New Drugs 2018; 36(1): 96 doi: 10.1007/s10637-017-0525-1
|
41 |
Faqiang Zhang, Mu Niu, Long Wang, Yanhong Liu, Likai Shi, Jiangbei Cao, Weidong Mi, Yulong Ma, Jing Liu. Systemic-Immune-Inflammation Index as a Promising Biomarker for Predicting Perioperative Ischemic Stroke in Older Patients Who Underwent Non-cardiac Surgery. Frontiers in Aging Neuroscience 2022; 14 doi: 10.3389/fnagi.2022.865244
|
42 |
Daniel J Craig, Nisha S Nanavaty, Monika Devanaboyina, Laura Stanbery, Danae Hamouda, Gerald Edelman, Lance Dworkin, John J Nemunaitis. The Abscopal Effect of Radiation Therapy. Future Oncology 2021; 17(13): 1683 doi: 10.2217/fon-2020-0994
|
43 |
Chunguo Cui, Bo Yu, Qi Jiang, Xingfang Li, Kaiyao Shi, Zecheng Yang. The roles of PD‐1/PD‐L1 and its signalling pathway in gastrointestinal tract cancers. Clinical and Experimental Pharmacology and Physiology 2019; 46(1): 3 doi: 10.1111/1440-1681.13028
|
44 |
Kai Sun, Xue-de Zhang, Xiao-yang Liu, Pei Lu. YAP1 is a Prognostic Biomarker and Correlated with Immune Cell Infiltration in Pancreatic Cancer. Frontiers in Molecular Biosciences 2021; 8 doi: 10.3389/fmolb.2021.625731
|
45 |
Shifaa Abdin, Dana Zaher, El-Shaimaa Arafa, Hany Omar. Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors. Cancers 2018; 10(2): 32 doi: 10.3390/cancers10020032
|
46 |
Madanraj Appiya Santharam, Vignesh Dhandapani. Exploring Pancreatic Metabolism and Malignancy. 2019; : 133 doi: 10.1007/978-981-32-9393-9_8
|
47 |
Liming Zhang, Wei Wang, Ruikun Wang, Nianchao Zhang, Hang Shang, Yang Bi, Da Chen, Cuizhu Zhang, Long Li, Jie Yin, Hongkai Zhang, Youjia Cao. Reshaping the Immune Microenvironment by Oncolytic Herpes Simplex Virus in Murine Pancreatic Ductal Adenocarcinoma. Molecular Therapy 2021; 29(2): 744 doi: 10.1016/j.ymthe.2020.10.027
|
48 |
Roland Andersson, Caj Haglund, Hanna Seppänen, Daniel Ansari. Pancreatic cancer – the past, the present, and the future. Scandinavian Journal of Gastroenterology 2022; 57(10): 1169 doi: 10.1080/00365521.2022.2067786
|
49 |
Javed Mahmood, Hem D. Shukla, Sandrine Soman, Santanu Samanta, Prerna Singh, Shriya Kamlapurkar, Ali Saeed, Neha P. Amin, Zeljko Vujaskovic. Immunotherapy, Radiotherapy, and Hyperthermia: A Combined Therapeutic Approach in Pancreatic Cancer Treatment. Cancers 2018; 10(12): 469 doi: 10.3390/cancers10120469
|
50 |
Mohammad Hosein Aziz, Kostandinos Sideras, Nasir Ahmad Aziz, Katya Mauff, Roel Haen, Daphne Roos, Lawlaw Saida, Mustafa Suker, Erwin van der Harst, Jan Sven Mieog, Bert A. Bonsing, Yarne Klaver, Bas Groot Koerkamp, Casper H. van Eijck. The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels. Annals of Surgery 2019; 270(1): 139 doi: 10.1097/SLA.0000000000002660
|
51 |
Aubrey L. Miller, Patrick L. Garcia, Karina J. Yoon. Developing effective combination therapy for pancreatic cancer: An overview. Pharmacological Research 2020; 155: 104740 doi: 10.1016/j.phrs.2020.104740
|
52 |
Gustavo A. Arias-Pinilla, Helmout Modjtahedi. Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities. Cancers 2021; 13(8): 1781 doi: 10.3390/cancers13081781
|
53 |
Feng Cao, Jia Li, Ang Li, Fei Li. Prognostic significance of positive peritoneal cytology in resectable pancreatic cancer: a systemic review and meta-analysis. Oncotarget 2017; 8(9): 15004 doi: 10.18632/oncotarget.14745
|
54 |
Marie Rouanet, Marine Lebrin, Fabian Gross, Barbara Bournet, Pierre Cordelier, Louis Buscail. Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes. International Journal of Molecular Sciences 2017; 18(6): 1231 doi: 10.3390/ijms18061231
|
55 |
Christophe Glorieux, Xiaojun Xia, Xin You, Zining Wang, Yi Han, Jing Yang, Gauthier Noppe, Christophe de Meester, Jianhua Ling, Annie Robert, Hui Zhang, Sheng-Ping Li, Huamin Wang, Paul J. Chiao, Li Zhang, Xiaobing Li, Peng Huang. Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer. Journal of Advanced Research 2022; 40: 109 doi: 10.1016/j.jare.2021.12.005
|
56 |
Ingrid Garajová, Andrea Cavazzoni, Michela Verze, Roberta Minari, Giuseppe Pedrazzi, Rita Balsano, Fabio Gelsomino, Raffaele Dalla Valle, Graziana Digiacomo, Elisa Giovannetti, Francesco Leonardi. It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer. Life 2022; 12(7): 960 doi: 10.3390/life12070960
|
57 |
Jinping Zhang, Shuman Zhang, Isabella Dörflein, Xiaofan Ren, Susanne Pfeffer, Nathalie Britzen-Laurent, Robert Grützmann, Xianglong Duan, Christian Pilarsky. Impact of CRISPR/Cas9-Mediated CD73 Knockout in Pancreatic Cancer. Cancers 2023; 15(19): 4842 doi: 10.3390/cancers15194842
|
58 |
Michail Galanopoulos, Aris Doukatas, Filippos Gkeros, Nikos Viazis, Christos Liatsos. Room for improvement in the treatment of pancreatic cancer: Novel opportunities from gene targeted therapy. World Journal of Gastroenterology 2021; 27(24): 3568-3580 doi: 10.3748/wjg.v27.i24.3568
|
59 |
Mengmeng Chen, Jian Jiang, Junyu Chen, Mengqi Wang, Yaci Lu, Lei Liu, Lijing Zhao, Lisheng Wang. The Clinical Safety and Efficacy of Targeted PD-L1 Therapy with Durvalumab
in Solid Tumors. Current Drug Targets 2023; 24(7): 584 doi: 10.2174/1389450124666230330101651
|
60 |
Jing Guo, Yunbing Wang, Jinyun Chen, Wensheng Qiu, Wenzhi Chen. Systematic review and trial sequential analysis of high-intensity focused ultrasound combined with chemotherapy versus chemotherapy in the treatment of unresectable pancreatic ductal adenocarcinoma. International Journal of Hyperthermia 2021; 38(1): 1375 doi: 10.1080/02656736.2021.1962550
|
61 |
Ritu Pandey, Muhan Zhou, Shariful Islam, Baowei Chen, Natalie K Barker, Paul Langlais, Anup Srivastava, Moulun Luo, Laurence S. Cooke, Eric Weterings, Daruka Mahadevan. Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) in Pancreatic Ductal Adenocarcinoma (PDA): An integrative analysis of a novel therapeutic target. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-54545-9
|
62 |
Yuewen Zhang, Lei Wu, Zhao Wang, Jinpeng Wang, Shrabasti Roychoudhury, Bartlomiej Tomasik, Gang Wu, Geng Wang, Xinrui Rao, Rui Zhou. Replication Stress: A Review of Novel Targets to Enhance Radiosensitivity-From Bench to Clinic. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.838637
|
63 |
Mingjuan Lisa Zhang, Martha Bishop Pitman. Molecular Diagnostics in Cytopathology. 2019; : 355 doi: 10.1007/978-3-319-97397-5_15
|
64 |
Noah A. Cohen, Vivian E. Strong, Yelena Y. Janjigian. Checkpoint blockade in esophagogastric cancer. Journal of Surgical Oncology 2018; 118(1): 77 doi: 10.1002/jso.25116
|
65 |
Takashi Murakami, Yukihiko Hiroshima, Ryusei Matsuyama, Yuki Homma, Robert M. Hoffman, Itaru Endo. Role of the tumor microenvironment in pancreatic cancer. Annals of Gastroenterological Surgery 2019; 3(2): 130 doi: 10.1002/ags3.12225
|
66 |
Shengye Jin, Qin Wang, Hao Wu, Da Pang, Shouping Xu. Oncolytic viruses for triple negative breast cancer and beyond. Biomarker Research 2021; 9(1) doi: 10.1186/s40364-021-00318-4
|
67 |
Isabel Mejia, Sandhya Bodapati, Kathryn T. Chen, Begoña Díaz. Pancreatic Adenocarcinoma Invasiveness and the Tumor Microenvironment: From Biology to Clinical Trials. Biomedicines 2020; 8(10): 401 doi: 10.3390/biomedicines8100401
|